Relmada Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Relmada Therapeutics

08/08/2023 23:04

* Relmada Therapeutics Inc  RLMD.OQ  reported a quarterly
adjusted
loss of 84 cents​​ per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was for a loss
of 90 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Relmada Therapeutics Inc's reported EPS for the quarter
was a
loss of 84 cents​.
    * The mean earnings estimate of analysts had fallen by
about 13.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Relmada Therapeutics Inc shares had risen by 7.3% this
quarter and lost 24.4% so far this year.
    * The company reported a quarterly loss of $25.3 million.
    * Wall Street's median 12-month price target for Relmada
Therapeutics Inc is $6.75 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 10:04 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.90          -0.84          Beat
 Mar. 31 2023      -0.89          -0.87          Beat
 Dec. 31 2022      -1.33          -1.41          Missed
 Sep. 30 2022      -1.45          -1.31          Beat